Market Overview - Concerns over prolonged conflict in the Middle East have led to a surge in oil prices, with WTI crude surpassing $100 per barrel for the first time since 2022[1] - The US stock market showed mixed results, with the Dow Jones down 0.95% at 47,501.55 points, and the S&P 500 down 1.33% at 6,740.02 points[1] - The Shanghai Composite Index rose by 0.38% to 4,124.19 points, while the Shenzhen Component increased by 0.59%[1] Economic Indicators - The US non-farm payrolls unexpectedly decreased by 92,000 in February, raising concerns about a potential stagflation scenario as the unemployment rate rose to 4.4%[12] - Inflationary pressures are expected to complicate the Federal Reserve's interest rate decisions, with the market anticipating rates to remain unchanged in the upcoming meeting[12] Oil Market Dynamics - The ongoing conflict has disrupted oil trade routes, particularly through the Strait of Hormuz, leading to reduced production from major oil-exporting countries like Iraq and Kuwait[12] - The Trump administration has initiated a $20 billion maritime reinsurance plan to stabilize oil trade in the region amid rising prices[12] Sector Performance - The chemical sector showed strength, contributing to the overall market rebound in A-shares[1] - The Hong Kong market experienced volatility, with the Hang Seng Index closing up 1.72% at 25,757.29 points, driven by gains in technology and healthcare sectors[1] Corporate Developments - Yanzhou Coal Mining Company sold its 100% stake in Inner Mongolia Xintai Coal for RMB 3.05 billion, which is expected to positively impact its profits in 2026[15] - Longyuan Power reported a 0.73% year-on-year increase in power generation for February, with solar power generation up by 20.67%[15]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Abbisko Cayman Limited 和譽開曼有限責任公司 （於開曼群島註冊成立的有限公司） （股份代號：2256） 自願性公告 《柳葉刀》(The Lancet)發佈貝捷邁®全球III期MANEUVER研究結果 和譽開曼有限責任公司（「本公司」，連同其附屬公司統稱「本集團」）謹此隨附新 聞稿，以告知本公司股東及潛在投資者，本公司之附屬公司上海和譽生物醫藥科 技有限公司（「和譽醫藥」）宣佈，其自主研發的新型、口服、高選擇性且高效的小 分子CSF-1R抑制劑貝捷邁® （鹽酸匹米替尼膠囊，ABSK021）的全球多中心III期 MANEUVER研究結果，於3月5日（西歐時間）正式發表於國際醫學期刊《柳葉刀》 (The Lancet)1 。此次發表標誌着和譽醫藥這一創新療法在臨床研究質量、數據完 整性及國際學術認可度方面取得了重要里程碑。 承董事會命 和譽開曼有限責任公司 徐耀昌博士 主席 此為本公司刊 ...

Core Viewpoint - The announcement by He Yu-B (02256) regarding the acceptance of the New Drug Application (NDA) for the oral, highly selective, and effective small molecule CSF-1R inhibitor, Beijiemai (ABSK021), by the FDA marks a significant milestone for the treatment of TGCT patients [1][2]. Group 1: Drug Development and Approval - Beijiemai, developed by He Yu Pharmaceutical, has received FDA acceptance for its NDA, based on positive efficacy and safety results from the global Phase III MANEUVER study [1]. - The drug is expected to be commercially available globally through a partnership with Merck [1]. - Beijiemai was previously approved by the NMPA in China in December 2025 for symptomatic TGCT adult patients who may face functional limitations or severe complications from surgical removal [1]. Group 2: Clinical Efficacy and Safety - The Phase III study demonstrated statistically significant improvement in the objective response rate (ORR) for TGCT patients treated with Beijiemai, assessed at week 25 according to RECIST v1.1 standards [1]. - All secondary endpoints related to key clinical outcomes for TGCT patients showed significant and clinically meaningful improvements, including enhanced joint range of motion and physical function, as well as reduced stiffness and pain [2]. - Long-term data from a median follow-up of 14.3 months indicated a continuous increase in ORR for patients who received Beijiemai treatment from the start of the study [3]. Group 3: Market Potential and Clinical Need - TGCT is a rare locally aggressive tumor that can lead to joint swelling, stiffness, and limited mobility, significantly impacting patients' daily activities and quality of life [3]. - If untreated or recurrent, TGCT can cause irreversible damage to bones, joints, and surrounding tissues [3]. - The ongoing regulatory submissions for Beijiemai in major global markets position the drug as a promising daily oral treatment option that is effective and well-tolerated, addressing unmet clinical needs in the TGCT field [3].

Core Viewpoint - The announcement highlights the acceptance of the New Drug Application (NDA) for the novel oral, highly selective, and effective small molecule CSF-1R inhibitor, Beijimai (ABSK021), by the FDA for the treatment of TGCT patients, indicating a significant advancement in addressing an unmet clinical need in this rare tumor type [1][2]. Group 1 - Beijimai is developed by Shanghai Heyu Biopharmaceutical Technology Co., Ltd. and is licensed to Merck for global commercialization [1]. - The NDA acceptance is based on positive efficacy and safety results from the global multi-center, randomized, double-blind, placebo-controlled Phase III MANEUVER study [1]. - The study demonstrated a statistically significant improvement in the objective response rate (ORR) for TGCT patients treated with Beijimai, assessed at week 25 according to RECIST v1.1 criteria [1]. Group 2 - All secondary endpoints related to key clinical outcomes for TGCT patients showed significant and clinically meaningful improvements, including enhanced joint range of motion and physical function, as well as reductions in stiffness and pain [2]. - Long-term data with a median follow-up of 14.3 months indicated a sustained increase in ORR for patients who received Beijimai treatment from the start of the study [2]. - TGCT is a rare locally aggressive tumor that can lead to joint swelling, stiffness, and limited mobility, significantly impacting patients' daily activities and quality of life [2].

Core Viewpoint - The new drug application (NDA) for the oral, highly selective, and effective small molecule CSF-1R inhibitor, Beijiemai® (ABSK021), developed by the subsidiary of He Yu-B (02256.HK), has been officially accepted by the U.S. Food and Drug Administration (FDA) for the systemic treatment of patients with tenosynovial giant cell tumor (TGCT) [1]. Group 1 - The drug Beijiemai® is a novel oral treatment targeting CSF-1R, indicating a significant advancement in the therapeutic options for TGCT patients [1]. - The acceptance of the NDA by the FDA marks a critical milestone for the company and its product development pipeline [1].